Cystic Fibrosis News

Elexacaftor/tezacaftor/ivacaftor safely improved lung function and respiratory symptoms among children aged 6 to 11 years with the F508del/minimal function genotypes of cystic fibrosis, according to study results.

Healio Pulmonology has compiled the top news on cystic fibrosis posted in 2022.

Challenged urine bicarbonate excretion provided a simple and safe quantification of cystic fibrosis transmembrane conductance regulator function among adults with cystic fibrosis, according to data published in Annals of Internal Medicine.

Patients with cystic fibrosis who experience hemoptysis were found to be at higher risk for a lung transplant and death without a transplant, according to a study published in Annals of the American Thoracic Society.

Lumacaftor/ivacaftor appeared safe and well tolerated for up to 24 weeks in children aged 1 year to younger than 2 years homozygous for F508del-CFTR, according to a study in American Journal of Respiratory and Critical Care Medicine.

Marcus A. Mall, MD, whose work led to the development of the first triple therapy for patients with cystic fibrosis, won the Falling Walls Foundation’s Science Breakthrough of the Year in Life Sciences award, according to a press release.

Black and Asian infants with cystic fibrosis had the lowest rates of detection during newborn screening, whereas white infants had the highest rates, according to a study published in Pediatric Pulmonology.

Use of an oscillatory positive expiratory pressure device alone or with additional airway clearance improved lung function among children with cystic fibrosis, according to data presented at the North American Cystic Fibrosis Conference.

Sleep disorder screening in routine care identified issues among more than 25% of pediatric patients with cystic fibrosis, according to a poster presented at the North American Cystic Fibrosis Conference.

Patients receiving treatment for cystic fibrosis wore actigraphy sensors and cough monitoring systems for the majority of a 12-week period, according to a poster presented at the North American Cystic Fibrosis Conference.